Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Operations: 2009-2024

Historic Cash from Operations for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $5.4 million.

  • Anika Therapeutics' Cash from Operations rose 36.96% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 9.04%. This contributed to the annual value of $5.4 million for FY2024, which is 402.18% up from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Cash from Operations is $5.4 million, which was up 402.18% from -$1.8 million recorded in FY2023.
  • Anika Therapeutics' Cash from Operations' 5-year high stood at $13.1 million during FY2020, with a 5-year trough of -$1.8 million in FY2023.
  • Moreover, its 3-year median value for Cash from Operations was $4.4 million (2022), whereas its average is $2.7 million.
  • In the last 5 years, Anika Therapeutics' Cash from Operations crashed by 140.55% in 2023 and then skyrocketed by 402.18% in 2024.
  • Anika Therapeutics' Cash from Operations (MRY) stood at $13.1 million in 2020, then plummeted by 35.73% to $8.4 million in 2021, then plummeted by 47.49% to $4.4 million in 2022, then crashed by 140.55% to -$1.8 million in 2023, then surged by 402.18% to $5.4 million in 2024.
  • Its Cash from Operations was $5.4 million in FY2024, compared to -$1.8 million in FY2023 and $4.4 million in FY2022.